Hematopoiesis News Volume 13.00 | Jan 4 2022

    By
    Justin.choi
    -
    0
    19







    2022-01-04 | HN 13.00


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.00 – 4 January, 2022
    TOP STORY

    Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and Myc/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B Cell Lymphoma

    Researchers performed targeted next-generation sequencing, immunohistochemistry for MYC, BCL2, and FN1, and fluorescent multiplex immunohistochemistry for microenvironmental markers in a large cohort of diffuse large B cell lymphoma.
    [Clinical Cancer Research]

    Abstract

    How are humanized mouse models facilitating in vivo studies of hematopoiesis? Webinar by Dr. Satiro De Oliveria, UCLA
    PUBLICATIONSRanked by the impact factor of the journal

    SF3B1 Mutant-Induced Missplicing of MAP3K7 Causes Anemia in Myelodysplastic Syndromes

    Using isogenic SF3B1 wild-type and mutant cell lines, normal human CD34 cells, and myelodysplastic syndrome patient cells, the authors defined a previously unrecognized role of the kinase MAP3K7, encoded by a known mutant SF3B1-targeted transcript, in controling proper terminal erythroid differentiation.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    AMPK-PERK Axis Represses Oxidative Metabolism and Enhances Apoptotic Priming of Mitochondria in Acute Myeloid Leukemia

    Scientists found that selective AMP-activated protein kinase (AMPK)-activating compounds killed acute myeloid leukemia (AML) cells by rewiring mitochondrial metabolism that primed mitochondria to apoptosis by BH3 mimetics, holding therapeutic promise in AML.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Development of a Novel and Synthetic HematoMiR Technology That Broadly Modulates Quiescence of Stem Cells and Enhances HSC Expansion

    Researchers showed that HematoMiRs and their combinations targeting over 50 factors involved in HSC quiescence could induce robust ex vivo murine and human HSC expansion. In particular, HematoMiR-5 treatment enhanced cell cycle through down-regulation of negative cell cycle regulators in HSCs.
    [Cellular and Molecular Life Sciences]

    AbstractGraphical Abstract

    GFI1 Cooperates with IKZF1/IKAROS to Activate Gene Expression in T Cell Acute Lymphoblastic Leukemia

    The authors showed that in T cell acute lymphoblastic leukemia cells, growth factor independence-1 (GFI1) and IKAROS were transcriptional partners that co-occupied regulatory regions of hallmark T cell development genes.
    [Molecular Cancer Research]

    Abstract

    SORT1/LAMP2-Mediated Extracellular Vesicle Secretion and Cell Adhesion Are Linked to Lenalidomide Resistance in Multiple Myeloma

    Scientists showed the molecular and cellular mechanisms of lenalidomide resistance in multiple myeloma. In a comparison between lenalidomide-resistant cell lines and the parental cell lines, the extracellular vesicle secretion and adherence abilities were significantly elevated in the resistant cells.
    [Blood Advances]

    Abstract

    Monitoring of Post-Transplant MLL-PTD as Minimal Residual Disease Can Predict Relapse after Allogeneic HSCT in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Investigators retrospectively collected the clinical data of 48 patients with mixed-lineage leukemia (MLL)-partial tandem duplications (PTD) acute myeloid leukemia or myelodysplastic syndrome with excess blasts who underwent allogeneic hematopoietic stem cell transplantation (HSCT).
    [BMC Cancer]

    Full Article

    Targeting CD33 for Acute Myeloid Leukemia Therapy

    The authors analyzed the level of CD33 expression in patients with newly diagnosed acute myeloid leukemia and determined its correlation with clinical characteristics. Of the 86 patients, CD33-high was closely related to the patients with normal karyotype, high white blood cell count, and a high ratio of primitive cells.
    [BMC Cancer]

    Full Article

    Blinatumomab in Pediatric Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia: RIALTO Expanded Access Study Final Analysis

    The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific T cell engager molecule, for treatment of pediatric relapsed/refractory B cell precursor acute lymphoblastic leukemia were examined in an open-label, single-arm, expanded access study (RIALTO).
    [Blood Advances]

    Abstract

    Phase I Study of Anti-CD47 Monoclonal Antibody CC-90002 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

    In this first clinical, phase I, dose-escalation and -expansion study, scientists evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
    [Annals of Hematology]

    Abstract
    Are Your Pluripotent Stem Cells What You Think They Are? Explore Now.
    REVIEWS

    Post-Hematopoietic Stem Cell Transplantation Immune-Mediated Anemia: A Literature Review and Novel Therapeutics

    The authors summarize the literature on post-hematopoietic stem cell transplantation immune-mediated anemia with a focus on ABO and non-ABO blood group incompatibility, describe the underlying mechanism of anemia, and outline preventive and treatment approaches.
    [Blood Advances]

    Abstract

    Hematopoietic Stem Cell Gene Editing and Expansion: State-of-the-Art Technologies and Recent Applications

    Scientists present a summary and discussion of the implications of new approaches to improve hematopoietic stem cell transplantation-based therapy.
    [Experimental Hematology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

    Celularity, Inc. announced the FDA has granted Fast Track Designation for its non-genetically modified cryopreserved human placental HSC-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).
    [Celularity, Inc.]

    Press Release

    Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T Cell Leukemia/Lymphoma

    Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T cell leukemia/lymphoma.
    [Daiichi Sankyo Company, Limited]

    Press Release
    FEATURED EVENT

    12th AACR-JCA Conference: Breakthroughs in Cancer Research

    February 5 – 9, 2022
    Maui, Hawaii, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Technician – Advanced Technology Core Laboratory

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Researcher – CAR T Cells Engineered to Treat Multiple Myeloma

    Memorial Sloan Kettering – New York City, New York, United States

    Clinical Research Manager – Leukemia Clinical Trials

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Fellowship – Hematopoiesis and Leukemia

    The University of Texas Southwestern Medical Center – Dallas, Texas, United States

    Research Technician – Hematologic Disorders

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter